Weight change among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: Findings from a randomised, multicentre, open-label trial.

Show simple item record

dc.contributor.author Beksinska, M
dc.contributor.author Issema, R
dc.contributor.author Beesham, I
dc.contributor.author Lalbahadur, T
dc.contributor.author Thomas, K
dc.contributor.author Morrison, C
dc.contributor.author Hofmeyr, GJ
dc.contributor.author Steyn, PS
dc.contributor.author Mugo, N
dc.contributor.author Palanee-Phillips, T
dc.contributor.author Ahmed, K
dc.contributor.author Nair, G
dc.contributor.author Baeten, JM
dc.contributor.author Smit, J
dc.date.accessioned 2024-07-08T12:33:33Z
dc.date.available 2024-07-08T12:33:33Z
dc.date.issued 2021-04
dc.identifier.uri https://doi.org/10.1016/j.eclinm.2021.100800
dc.identifier.uri http://repository.kemri.go.ke:8080/xmlui/handle/123456789/662
dc.description.abstract Background: There is limited evidence on the impact of the use of progestin-only hormonal contraception (POC) on weight change. We conducted a secondary analysis of prospective weight change among women enrolled in the Evidence for Contraceptive options and HIV Outcomes (ECHO) trial. Methods: The ECHO trial was conducted at 12 sites in eSwatini, Kenya, South Africa and Zambia between December 2015 and October 2018. HIV negative, women aged 16-35 years, desiring contraception, were randomised (1:1:1) to either 3-monthly intramuscular depot medroxyprogesterone acetate (DMPA-IM), levonorgestrel (LNG) implant or copper intrauterine device (IUD). Follow-up was up to 18 months. Weight (kg) was measured at baseline and study exit. Analysis was performed as intention to treat (ITT) and time on continuous contraceptive use. The primary outcome of this secondary analysis is weight change from study enrolment to the final visit at study month 12-18. The ECHO trial is registered with ClinicalTrials.gov, NCT02550067. Findings: 7829 women were randomly assigned to DMPA-IM (n = 2609), copper IUD (n = 2607) or LNG implant (n = 2613). The ITT population included 7014 women 2293 DMPA-IM group, 2372 copper IUD group and 2349 LNG group) who were not lost to follow-up, pregnant on study, or missing weight data. The mean weight increased in all groups but was significantly different in magnitude: 3.5 kg (SD = 6.3), 2.4 kg (SD = 5.9) and 1.5 kg (SD = 5.7) in the DMPA-IM, LNG implant and copper IUD groups, respectively. Comparative differences between groups were (2.02 kg (95% CI, 1.68, 2.36, p < 0.001) for DMPA-IM versus copper IUD, 0.87 kg (0.53,1.20 p < 0.001) for LNG implant compared to copper IUD and 1.16 kg (0.82, 1.50, p < 0.001) for DMPA-IM compared with LNG implant. Results for continuous contraceptive use were similar. Interpretation: We found differences in weight gain between POC users compared to the nonhormonal copper IUD group over 12-18 months of use. Women using POCs should be counselled about this potential side effect when choosing a contraceptive method. en_US
dc.language.iso en en_US
dc.publisher EClinicalMedicine en_US
dc.subject Body mass index; Contraception; Copper intrauterine device; Depot medroxyprogesterone acetate; Levonorgestrel implant; Weight. en_US
dc.title Weight change among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: Findings from a randomised, multicentre, open-label trial. en_US
dc.type Article en_US


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account